J&J/Janssen win US OK for diabetes drug Invokamet
This article was originally published in Scrip
Executive Summary
The FDA on 8 August OK'd Janssen's Invokamet, a fixed-dose combination of canagliflozin and metformin, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.